Web Analytics

fundsforNGOs

Grants and Resources for Sustainability

You are here: Home / Latest Funds for NGOs and Calls for Proposals and Calls for Applications / RFPs: Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical Research

RFPs: Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical Research

Deadline: 20-Mar-25

The Pfizer is currently accepting proposals to support non-interventional Investigator Sponsored Research projects that will advance the understanding of IB6 patterns of expression and clinical outcomes in NSCLC or explore sigvotatug vedotin’s preclinical activity.

Project Types 
  • Organizations are invited to submit proposals for studies that fall into 1 of the following 2 categories:
    • Noninterventional, (retrospective or prospective studies) looking at integrin beta-6 (IB6) patterns of expression and clinical outcomes in NSCLC
    • Preclinical investigator-sponsored research exploring of sigvotatug vedotin’s preclinical activity in relevant tumor models
Area of Interest
  • This Research Grant RFP is seeking proposals in two types of non interventional research areas
    • Category 1: Noninterventional, (retrospective or prospective studies) looking at integrin beta-6 (IB6) patterns of expression and clinical outcomes in NSCLC
      • Pfizer’s interest is to better understand the following regarding IB6 expression:
        • Real-world prevalence and patterns of expression in IB6 high vs low expressors overall and in key subgroups (examples include histology, line of therapy, stage of disease, geographic / ethnic background, AGA population, age, gender, body weight, smoking status, and comorbidities)
        • Potential impact of IB6 expression on prognosis and other clinical outcomes
      • Grant recipients are expected to have access to a tumor bank for retrospective analyses or are able to prospectively collect tumor samples
      • To test for IB6 expression, grant recipients must be able to send samples (core-needle biopsies and/or resections; FNAB or cell blocks not supported) to a US-based clinical diagnostics laboratory which has been authorized and trained on a proprietary IB6 IHC assay to provide IB6 staining and analysis
    • Category 2: Preclinical investigator-sponsored research (not limited to NSCLC)
      • Exploration of sigvotatug vedotin’s preclinical activity in relevant tumor models
      • Investigation of potential immune modulatory effects of sigvotatug vedotin (an investigational IB6- directed ADC) in preclinical tumor models
Funding Information
  • Individual projects requesting up to $200,000 will be considered.
  • 18-month suggested project length (may be shorter or longer).
Eligibility Criteria
  • Geographic Scope/Location of Project/Study: Global
  • Applicant Eligibility Criteria
    • Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
    • The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a terminal degree in Pharmacy, Social Work, or other relevant discipline.
    • The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
    • The PI must be an employee or contractor of the requesting organization.
    • Requesting organization must be legally able to receive award funding directly from Pfizer Inc.

For more information, visit Pfizer.